CCS
RPRX icon

Concentric Capital Strategies’s Royalty Pharma RPRX Stock Holding History

Concentric Capital Strategies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,968
Closed -$2.66M – 367
2024
Q2 		$2.66M Buy
+100,968
New +$2.8M 0.13% 172
2022
Q4 		– Sell
-73,379
Closed -$2.95M – 202
2022
Q3 		$2.95M Buy
+73,379
New +$3.13M 1.04% 26

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concentric Capital Strategies's RPRX Position: Q3 2024 in Review

Concentric Capital Strategies sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 100,968 shares — an estimated $2.66M sold.

Concentric Capital Strategies first reported a position in RPRX in Q3 2022 and held it in 2 quarters. The position peaked at $2.95M in Q3 2022. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Concentric Capital Strategies reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Concentric Capital Strategies sold 100,968 Royalty Pharma shares in Q3 2024, an estimated $2.66M.
  • Concentric Capital Strategies first reported a position in Royalty Pharma in Q3 2022 and held it in 2 quarters.
  • Concentric Capital Strategies's Royalty Pharma position peaked at $2.95M in Q3 2022.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Concentric Capital Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.